



## Duzallo

Procedural steps taken and scientific information after the authorisation

| Application number  | Scope  | Opinion/ Notification <sup>1</sup> issued on | Commission Decision Issued <sup>2</sup> / amended on | Product Information affected <sup>3</sup> | Summary                           |
|---------------------|--|--|--|---|-----------------------------------|
| PSUSA/10704 /201912 | Periodic Safety Update EU Single assessment - allopurinol / lesinurad  | 09/01/2020                                   | n/a  |   | PRAC Recommendation - maintenance |
| PSUSA/10704 /201906 | Periodic Safety Update EU Single assessment - allopurinol / lesinurad  | 16/01/2020                                   | n/a  |   | PRAC Recommendation - maintenance |
| IB/0003             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension of introduction of a | 26/08/2019                                   | n/a  |   |                                   |

<sup>1</sup> Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

<sup>2</sup> A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

<sup>3</sup> SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



|                     |  |            |    |                        |                                   |
|---------------------|--|------------|----|------------------------|-----------------------------------|
|                     | re-test period/storage period supported by real time data  |            |    |                        |                                   |
| IB/0002/G           | <p>This was an application for a group of variations.</p> <p>B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes</p> <p>B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes</p> | 31/07/2019 |    | SmPC, Labelling and PL |                                   |
| PSUSA/10704 /201812 | Periodic Safety Update EU Single assessment - allopurinol / lesinurad  | 11/04/2019 | /a |                        | PRAC Recommendation - maintenance |

Medicinal product no longer authorised